The application of ribozymes to HIV infection

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 3, 1999, Pages 316-322

  Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOZYME;

ANTIVIRAL ACTIVITY; CATALYSIS; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

ANIMALS; ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COHORT STUDIES; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GAMMARETROVIRUS; GENE THERAPY; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; MICE; NUCLEIC ACID CONFORMATION; RECEPTORS, CCR5; RNA; RNA, CATALYTIC; RNA, MESSENGER; RNA, TRANSFER, LYS; RNA, VIRAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032993464     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Chun TW, Chadwick K, Margolick J, Siliciano RF: Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI. J Virol (1997) 71(6):4436-4444.
2. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch Crovo P, Siliciano RF: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 387(6629):183-188.
3. Perelson AS, Essunger P, Ho DD: Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS (1997) 11(Suppl A):S17-S24.
4. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 387(6629):188-191. •• Based on HIV-1 decay characteristics in patients on triple drug therapy, these investigators estimate that 2.3 to 3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from lymphoid compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.
5. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR: Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell (1982) 31(1):147-157.
6. Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S: The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell (1983) 35(3 Pt 2):849-857.
7. Rossi JJ: Practical ribozymes. Making ribozymes work in cells. Curr Biol (1994) 4(5):469-471.
8. Rossi JJ, Sarver N: Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents. Adv Exp Med Biol (1992) 312:95-109.
9. Castanotto D, Rossi JJ, Deshler JO: Biological and functional aspects of catalytic RNAs. Crit Rev Eukaryot Gene Expr (1992) 2(4):331-357.
10. Tuschl T, Gohlke C, Jovin TM, Westhof E, Eckstein F: A three-dimensional model for the hammerhead ribozyme based on fluorescence measurements. Science (1994) 266(5186):785-789.
11. Scott WG, Finch JT, Klug A: The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage. Cell (1995) 81(7):991-1002.
12. Scott WG, Finch JT, Klug A: The crystal structure of an all-RNA hammerhead ribozyme. Nucleic Acids Symp Ser (1995) 34:214-216.
13. Scott WG, Murray JB, Arnold JRP, Stoddard BL, Klug A: Capturing the structure of a catalytic RNA intermediate: the hammerhead ribozyme. Science (1996) 274(5295):2065-2069.
14. Scott WG, Klug A: Ribozymes: structure and mechanism in RNA catalysis. Trends Biochem Sci (1996) 21(6):220-224.
15. Pley HW, Flaherty KM, McKay DB: Three-dimensional structure of a hammerhead ribozyme. Nature (1994) 372(6501):68-74.
16. Haseloff J, Gerlach WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. 1988. Biotechnology (1992) 24:264-269.
17. Ruffner DE, Stormo GD, Uhlenbeck OC: Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry (1990) 29(47):10695-10702.
18. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ: Ribozymes as potential anti-HIV-1 therapeutic agents. Science (1990) 247(4947):1222-1225. • The first use of ribozymes against HIV-1. Human cells stably expressing a hammerhead ribozyme targeted to HIV-1 gag transcripts were challenged with HIV-1, a substantial reduction in the level of HIV-1 gag RNA relative to that in nonribozyme-expressing cells, was observed. The reduction in gag RNA was reflected in a reduction in antigen p24 levels. The results from this study demonstrated the feasibility of developing ribozymes as therapeutic agents against human pathogens such as HIV-1.
19. Yu M, Ojwang J, Yamada O, Hampel A, Rapapport J, Looney D, Wong-Staal F: A hairpin ribozyme inhibits expression of diverse strains of human Immunodeficiency virus type 1. Proc Natl Acad Sci USA (1993) 90(13):6340-6344. • A hairpin ribozyme targeted to a highly conserved site in the 5′ LTR region of HIV-1 was expressed from various promoters in a retroviral vector backbone. Most importantly, this study demonstrates that inhibition of expression of diverse strains of HIV-1 can be achieved by this hairpin ribozyme targeting the U5 region of the HIV LTR.
20. Yamada O, Yu M, Yee JK, Kraus G, Looney D, Wong-Staal F: Intracellular Immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther (1994) 1(1):38-45.
21. Leavitt MC, Yu M, Yamada O, Kraus G, Looney D, Poeschla E, Wong-Staal F: Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum Gene Ther (1994) 5(9):1115-1120.
22. Yamada O, Kraus G, Leavitt MC, Yu M, Wong-Staal F: Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells. Virology (1994) 205(1):121-126.
23. Crisell P, Thompson S, James W: Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro. Nucleic Acids Res (1993) 21(22):5251-5255.
24. James W, Crisell P, Rhodes A: Gene inhibition of HIV-1 replication. A comparative and mechanistic study. Ann NY Acad Sci (1992) 660:274-275.
25. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F, Rappaport J: Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA (1992) 89(22):10802-10806.
26. Lo KM, Biasolo MA, Dehni G, Palu G, Haseltine WA: Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology (1992) 190(1):176-183.
27. Zhou C, Bahner IC, Larson GP, Zaia JA, Rossi JJ, Kohn EB: Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene (1994) 149(1):33-39. •• Two hammerhead ribozymes, on targeting a site in the tat gene, and another targeting a common exon shared by tat and rev were co-expressed from a retroviral vector LTR. Cultured T-lymphocytes expressing these dual ribozymes were resistant to HIV-1 challenge during long-term culturing. An important control in this study was the use of mutant, crippled ribozyme controls which were not able to confer protection on challenged T-lymphocytes. The combination of the murine retroviral vector expressing the dual ribozymes is currently being tested in a human gene therapy trial for AIDS/lymphoma patients.
28. Zhou C, Bahner I, Rossi JJ, Kohn DB: Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral Inhibition. Antisense Nucleic Acid Drug Dev (1996) 6(1):17-24.
29. Chen CJ, Banerjea AC, Haglund K, Harmison GG, Schubert M: Inhibition of HIV-1 replication by novel multitarget ribozymes. Ann NY Acad Sci (1992) 660:271-273.
30. Weerasinghe M, Liem SE, Asad S, Read SE, Joshi S: Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol (1991) 65(10):5531-5534.
31. Michienzi A, Conti L, Varano B, Prislei S, Gessani S, Bozzoni I: Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line. Hum Gene Ther (1998) 9(5):621-628. • T-lymphoblastoid cell line. The antiviral activity of ribozymes specifically designed to co-localize inside the nucleus with the Rev pre-mRNA before it is spliced and transported to the cytoplasm were tested in a T-cell line. The ribozyme was inserted in a derivative of spliceosomat U1 small nuclear RNA that had perfect complementarity with the 5′ splice site of the Rev pre-mRNA. These chimeric ribozymes markedly reduced viral antigen levels along with intracellular viral RNA transcripts. The control disabled ribozymes were inefficient inhibitors, demonstrating cleavage specificity of the ribozyme activity.
32. Gervaix A, Li X, Kraus G, Wong-Staal F: Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol (1997) 71(4):3048-3053. • The combination of a ribozyme targeting the HIV-1 U5 region with a Rev binding decoy was initially demonstrated to be more effective than antiviral RNA alone. In this study, the anti-U5 ribozyme-decoy combination under control of a Pol III promoter is cloned as a double copy insert in a retroviral viral vector LTR. A second ribozyme targeting env/rev linked to the same decoy was inserted as a single copy under control of the vector LTR promoter. These multigene antiviral vectors when transduced or transfected into human CD4+ T-cells showed marked resistance to challenge with multiple subtypes (clades A to E) of HIV-1.
33. Kuwabara T, Amontov SV, Warashina M, Ohkawa J, Taira K: Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes. Nucleic Acids Res (1996) 24(12):2302-2310.
34. Ramezani A, Ding SF, Joshi S: Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Gene Ther (1997) 4(8):861-867. • Retroviral vectors were engineered to express multimeric hammerhead ribozymes targeting nine highly conserved sites within the HIV-1 envelope (Env) coding region. A human CD4+ T-lymphocyte-derived MT4 cell line was stably transduced with retroviral vectors expressing these ribozymes. As compared with the control cells lacking any ribozyme, HIV-1 replication was was almost completely inhibited in multimeric RzEnv1-9-expressing cells and no viral RNA or protein could be detected for up to 60 days. The use of such multimeric ribozyme expression units may be the most efficacious way of circumventing viral resistance to ribozymes in a gene therapy setting.
35. Chen CJ, Banerjea AC, Harmison GG, Haglund K, Schubert M: Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res (1992) 20(17):4581 -4589. • These studies provided the first demonstration that multimeric ribozyme transcripts could be simultaneously expressed and functionally active in human cells. Nine different ribozymes targeting sites in the HIV-1 env gene were co-expressed and provided strong inhibition of HIV-1 in cultured cells.
36. Li X, Gervaix A, Kang D, Law P, Spector SA, Ho AD, Wong-Staal F: Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies. Gene Ther (1998) 5(2):233-239.
37. Rosenzweig M, Marks DF, Hempel D, Heusch M, Kraus G, Wong-Staal F, Johnson RP: Intracellular immunization of rhesus CD34+ hematopoietic progenitor cells with a hairpin ribozyme protects T cells and macrophages from simian immunodeficiency virus infection. Blood (1997) 90(12):4822-4831.
38. Yu M, Leavitt MC, Maruyama M, Yamada O, Young D, Ho AD, Wong-Staal F: Intracellular Immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human Immunodeficiency virus type 1. Proc Natl Acad Sci USA (1995) 92(3):699-703.
39. Wang L, Witherington C, King A, Gerlach WL, Carr A, Penny R, Cooper D, Symonds G, Sun LQ: Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum Gene Ther (1998) 9(9):1283-1291. • A hammerhead ribozyme targeted to a site in the HIV-1 tat gene was expressed from a retroviral LTR in cultured T-lymphocytes. Long-term challenge of these cells with HIV-1 revealed marked protection and no breakthrough of resistant viral mutants. This ribozyme has now entered a phase I clinical trial.
40. Wong-Staal F, Poeschla EM, Looney DJ: A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 Infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther (1998) 9(16):2407-2425. •• Autologous gene-altered T-cells were infused into asymptomatic HIV-1 seropositive individuals in a phase I human gene therapy trial. The objectives of this trial were to test the safety, feasibility and potential efficacy of T-cell ribozyme gene therapy for the treatment of HIV-1 infection. Autologous CDB-depleted mononuclear cells were transduced with ribozyme expressing or a control murine retroviral vector. The transduced cells were expanded ex vivo in the presence of a anti-HIV-1 drug. The cells were subsequently infused into patients. In addition to the safety aspects of this trial, in vivo survival of control and ribozyme-transduced cells was carefully followed by PCR analyses. Preliminary results from this trial have indicated that transduced cells can persist for long intervals in HIV-infected subjects and ribozyme-transduced cells may possess a survival advantage in vivo.
41. Bauer G, Valdez P, Keams K, Bahner I, Wen SF, Zaia JA, Kohn DB: Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood (1997) 89(7):2259-2267. •• Granulocyte colony-stimulating factor mobilized peripheral blood CD34+ cells were isolated from HIV-1-infected individuals and transduced with retroviral vectors containing three different anti-HIV-1-genes: the Rev binding domain of the Rev responsive element, a double hammerhead ribozyme vector targeted to cleave the tat and rev transcripts, and a trans-dominant mutant of rev (M10). The RRE decoy, anti-tat/rev ribozymes and transdominant M10 transduced cultures when challenged with both laboratory and primary isololates of monocytotropic HIV-1 strains displayed up to 1,000-fold inhibition of HIV-1 replication. Growth of the hematopoietic cells in long-term bone marrow culture was not perturbed by the expression of any of the anti-HIV-1 genes. The ribozyme and vector combination used in this preclinical study is currently being tested in two separate phase I/II clinical trials in which CD34+ cells are transduced and reinfused into HIV-1 infected individuals. Thus, this is an important preliminary study to two novel gene therapy protocols.
42. Ho AD, Li X, Lane TA, Yu M, Law P, Wong-Staal F. Stem cells as vehicles for gene therapy: novel strategy for HIV infection. Stem Cells (1995) 13 (Suppl 3):100-105.
43. Gervaix A, Schwarz L, Law P, Ho AD, Looney D, Lane T, Wong-Staal F: Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-lnfected individuals. Hum Gene Ther (1997) 8(18):2229-2238.
44. Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kohn D, Engelke D, Rossi JJ: The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA (1997) 3(1):75-88.
45. Morgan RA, Anderson WF: Human gene therapy. Annu Rev Biochem (1993) 62:191-217.
46. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividlng cells by a lentiviral vector. Science (1996) 272(5259):263-267.
47. Dropulic B, Hermánkova M, Pitha PM: A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci USA (1996) 93(20):11103-11108.
48. Podsakoff G, Wong KK Jr, Chatterjee S: Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol (1994) 68(9):5656-5666.
49. Chatterjee S, Li W, Wong CA, Fisher-Adams G, Lu D, Guha M, Macer JA, Forman SJ, Wong KK Jr: Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood (1999) 93(6):1882-1894.
50. Fisher-Adams G, Wong KK Jr, Podsakoff G, Forman SJ, Chatterjee S: Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood (1996) 88(2):492-504.
51. Chatterjee S, Johnson PR, Wong KK Jr: Dual-target Inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science (1992) 258(5087):1485-1488.
52. Westaway SK, Cagnon L, Chang Z, Li S, Li H, Larson GP, Zaia JA, Rossi JJ: Virion encapsidation of tRNA(3Lys)-ribozyme chimeric RNAs inhibits HIV infection. Antisense Nucleic Acid Drug Dev (1998) 8(3):185-197. • This study exploited the fact that retrovirvses require a specific host cellular tRNA primer for initiation of first-strand DNA synthesis by designing and testing of an antiviral ribozyme fused to tRNA(3Lys), the primer used for HIV-1 replication. The chimera of tRNA (3Lys) covalently attached to a hammerhead ribozyme targeted to the region immediately upstream of the primer binding site of the HIV-1 genome was expressed from either the tRNA (3Lys) intragenic RNA polymerase III promoter or from a human U6 snRNA promoter. The chimeric constructs were co-transfected with HIV-1 proviral DNA into human cells. This study demonstrated encapsidation of the tRNA (3Lys)-ribozymes in HIV-1 virions. This resulted in a substantial reduction in the level of infectious virus produced from these co-transfected cells. These results demonstrated a potent form of co-localizing a ribozyme to the HIV-1 proviral RNA as a potential form of anti-HIV-1 ribozyme therapy.
53. Westaway SK, Larson GP, Li S, Zaia JA, Rossi JJ: A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly. Nucleic Acids Symp Ser (1995) 33:194-199.
54. Yamada O, Kraus G, Luznik L, Yu M, Wong-Staal F: A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol (1996) 70(3):1596-1601.
55. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA: CC CKR5: a RANTES, MIP-1 alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272(5270):1955-1958.
56. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381(6584):667-673.
57. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Liftman DR, Landau NR: Identification of a major co-receptor for primary Isolates of HIV-1. Nature (1996) 381(6584):661-666.
58. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272(5263):872-877.
59. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 85(7):1135-1148.
60. Rana S, Besson G, Cook DG, Rucker J, Smyth RJ, Yi Y, Turner JD, Quo HH, Du JG, Peiper SC, Lavi E, Samson M, Libert F, Uesnard C, Vassart G, Doms RW, Parmentier M, Collman RG: Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta CCR5 mutation. J Virol (1997) 71(4):3219-3227.
61. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T: HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med (1997) 3(3):252-253.
62. Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennetts BH, Newcombe NR, Benson EM, Carr A, Cooper DA, Kaldor JM: Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS (1997) 11(15):1833-1838.
63. Samson M, Libert F, Doranz BJ, Rucker J, Uesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Vertiofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 382(6593):722-725. •• The chemokine receptor CCR5 is co-receptor for macrophage-tropic (M-tropic) HIV-1 strains. These investigators demonstrate that a mutant allele of CCP5 is present at a high frequency in Caucasian populations. This mutant allele harbors a 32 bp deletion within the coding region generating a non-functional receptor that does not support membrane fusion or infection by macrophage- and dual-tropic HIV-1 strains. Analyses of a cohort of HIV-1 infected Caucasian subjects resulted in no individuals homozygous for the mutation found. When lymphocytes from an individual homozygous for the null allele were tested for susceptibility to HIV-1 infection, they were found to be highly resistant to infection by M-tropic HIV-1 viruses. These investigators also noted that the lower frequency of heterozygotes in HIV-1 seropositive patients may indicate partial resistance to viral infection. These studies led to a number of investigations into how to block this receptor to prevent HIV-1 infection.
64. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 272(5265):1167-1170.
65. Carroll RG, Riley JL, Levine BL, Feng Y, Kaushal S, Ritchey DW, Bernstein W, Weislow OS, Brown CR, Berger EA, June CH, St Louis DC: Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science (1997) 276(5310):273-276.
66. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TNC, Proudfoot AE: Potent Inhibition of HIV-1 infactivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 276(5310):276-279.